News | October 14, 2024
Indian drug regulator recommends Wockhardt's Miqnaf for treatment of CABP
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
The partnership marks a pivotal step towards developing new therapies for combating Sickle Cell Disease
The new facility uses the latest mammalian systems and single-use technology, including a production line with eight 2,000 L bioreactors
The GMP certificate will allow the manufacturing site in Hervás, Cáceres to manufacture active ingredients for the pharmaceutical industry that is based on medicinal plants
This product is categorized as antacids, antiflatulents and anti-Ulcerants
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
Paliperidone extended-release tablets will be produced at the Group’s manufacturing site at SEZ, Ahmedabad
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
Approval is based on Phase III INAVO120 results, showing the Itovebi (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting
Subscribe To Our Newsletter & Stay Updated
